The images are damning $IOVA durability fell off a cliff after they switched from high to low dose lymphodepletion bc the high dose was too toxic (incl pt death)
How is FDA going to allow a pivotal trial based on such a small, weak sample and insuff time to assess AEs
There's no way to be *100%* certain that these swimmers precisely break down 1st cut patients versus 2nd cut patients for
$IOVA
, but you can tell quite well by comparing the old/new swimmers. If this is off, it is only off slightly.
Look at this...The new patients' durability of response is HORRIBLE. I have no idea how management is getting away with saying that durability was consistent!
Unless those 2 uPR patients convert to the longest durability the new new cut cohort has seen...mDOR for the new patients looks like it is tracking around ~6 months!!! Versus "not met at 25.4 months" previously!
mDOR of the old cut is >25 months. mDOR of the new cut is at serious risk of being only ~6 months (a SINGLE relapse among 4 current responders would lock it in at ~6 months).
Isn't the FDA going to look at these as totally different populations? The old and new cut patients GOT DIFFERENT TREATMENT REGIMENS! And we are seeing massively different durability efficacy results...PROBLEM.
The old patients that have solid durability were all on the high dose chemo LD regimen - but that got axed because it killed somebody. Now, all the new patients with terrible response durability are on a new, low dose chemo LD regimen. THIS is the regimen that is ACTUALLY being taken forward, so THIS IS THE COHORT OF PATIENTS WE SHOULD ASSESSING EFFICACY/DURABILITY FROM. It is not looking pretty *at all*. The old data from the more intense regimen help to hide that fact a *little* bit from investors, but there's no hiding this from the FDA and clinicians.
The "good" data here all come from a regimen that
$IOVA
isn't even using anymore! This will be a huge regulatory (not to mention commercial) issue if the new cut patients' mDOR actually does come in this poor (which looks like a very high probability).
They went from mDOR >25 months to clearly <12 months, and potentially as low as ~6 months...and they are telling you the durability data are "cosistent". Give me a break...this is egregious!
G5 TRAE imbalance w/2 deaths related to boosted IO tox - 1 myositis/myocarditis + 1 myasthenia gravis- is an extremely concerning AE profile for a neoantigen vaccine
Unless these occurred pre-vaccine, I’d worry tox may be attributable to $MRNA’s intismeran
#ESMO26 INTerpath-001
8 Grade 5 AEs in the experimental arm, 0 in the control arm.
Of course, it could all be pure coincidence! After all, 6 of the 8 events were not considered TRAE
Perhaps it was just the excitement of being randomized to the experimental arm?
I'm genuinely curious about the independent causality assessment.
I understand that 3 of the 8 G5 AEs (all in drug arm) occurred after the mRNA vaccine was given.
Does anyone know if they specified re: these two that are clearly IO-related?
These are the type of extremely rare irAEs which I would worry could be amplified by neoantigens
Epoch retweeted
$MRK $MRNA data amazing HR .58. So $MRK $MRNA data leaked to this website which is now down. HR is .58. oncology-central.com/interpa…
$IRON has first-in-class tx for vampirism
Increase in average monthly total time in light without pain during month 6 (+12.2 hours vs. placebo, p=0.0010)
Congrats to all phlebotomists
1
11
1,976
TL;DR: GILD Oral a4b7 got its headline 22.6% remission delta in highest dose but dose response funky (pooled 11% delta) & do people really have no memory of MORF PTGX? (8-13% Ph2 delta, oral a4b7)
If $ABVX had same baseline chars, they’d have 20% remission delta 4 wks sooner
22.6% remission delta for high dose Emvistegrast Ph2 will not reproduce in ph3 🧵
1. Efficacy by doses vary wildly; next highest dose arm is 1% delta. Pooled dose delta is 11%.
2. The real delta for oral a4b7 class @ 12 wk is likely 13-15% at best dose (see comps below)
1/n
2. Even Entyvio only gets to ~25% delta after a YEAR on therapy; there is no real rationale for oral to improve on efficacy here
3. Unlike obefazimod, emvistegrast excludes 3L+ pts, which was 15.7% of ABVX's trial
If $ABVX excluded them, high dose delta would be 18%--at *wk 8*
1
13
1,896
4. If $ABVX had similar 78% AT-naive and 3L+ excluded, clinical remission would be 20% *at wk 8*
That’s instead of wk 12 & in a massive Ph3 of >1000 pts, not an n=59 dose arm
*These adjustments are estimated based on using ABVX subgroup analysis of remission delta by AT
$ABVX in 2026 vs 2025
Omvoh
$lly Omvoh new composite outcomes data shared today. Cross trial comp with Obe $abvx below. Cc @DaveARicks prnewswire.com/news-releases…
1
35
3,829
$NKTR is pursuing horizontal integration w/new product line to corner the market via mass production of bagholders
24
1,660
This drug name gets longer every time I look at it! $NKTR
If rezpeg wasn’t active in AA, wouldn’t expect this durability—suggests to me it didn’t produce its AA signal on stats games

















